FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Advanced Esophageal Carcinoma Clinical Trial

Official title:

Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02023593
• Other study ID #: FOLFIRI-29
• Status: Completed
• Phase: Phase 2
• Start date: March 2012
• Est. completion date: December 2022

Study information

• Verified date: February 2023
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase Ⅱ study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.

Description:

Although there are no standard second-line treatment for metastatic esophageal carcinoma, some studies have showed that irinotecan, fluorouracil may be effective in treating patients with metastatic esophageal carcinoma after failure of first-line treatment. Since irinotecan, fluorouracil, and leucovorin work in different ways to stop the growth of tumor. Giving more than one drug may be more effective. In this phase Ⅱ trial, the investigator would like to observe the efficacy and safety of FOLFIRI(Irinotecan/5-FU/leucovorin ) as second-line treatment for metastatic esophageal carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: December 2022
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients have provided a signed Informed Consent Form
• Karnofsky score =70
• Age: 18-75 years old
• Histologically confirmed diagnosis of advanced esophageal carcinoma
• Patients have Received and progressed on first-line treatment, and not received CPT-11 or Fluoropyrimidine based palliative chemotherapy
• Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria
• Life expectancy = 3 months
• Patient has adequate bone marrow and organ function
• Absolute Neutrophil Count (ANC) = 1.5 x 109/L
• Platelets = 75 x 109/L
• Hemoglobin = 9.0 g/dL
• Patient has adequate liver function
• AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis)
• Serum bilirubin = 2 x ULN
• Creatinine = 1.5 times ULN
• Good compliance

Exclusion Criteria:

• Pregnant or lactating women
• Brain metastasis or only with bone metastasis.
• Patients with severe infection or active peptic ulcer which need treatment
• Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases
• Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ
• Psychiatric illness that would prevent the patient from giving informed consent
• Patient is concurrently using other approved or investigational antineoplastic agent

Related Conditions & MeSH terms

• Advanced Esophageal Carcinoma
• Carcinoma
• Esophageal Neoplasms

Intervention

Drug:
• FOLFIRI
Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Yuhong Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease control rate		Up to 24 weeks
Secondary	Overall survival		From the date of first drug administration until the date of death, assessed up to 60months
Secondary	Adverse events	Safety profile will be assessed using the NCI CTCAE version 3.0	Each follow up visit, assessed up to 24 weeks
Secondary	Progression free survival		From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months